Table 3 Clinical Characteristics of Non-infectious Scleritis Cases Treated with Rituximab

Granulomatosis with Polyangiitis (GPA)

75 (62.0%)

Mean: 48.2 ± 16.0 Median: 50.0

Range: 21.0–72.0

M:F

0.80:1

Unspecified scleritis (35/75, 46.7%);

Anterior scleritis (34/75, 45.3%);

Posterior scleritis (3/75, 4.0%);

Episcleritis (2/75, 2.7%);

Anterior and posterior scleritis (1/75, 1.3%)

Mean: 30.9 ± 29.5

Median: 21

Range: 1–96

Rheumatologic (57/68, 83.8%);

Foster (4/68, 5.9%);

Other (4/68, 5.9%);

Oncologic (3/68, 4.4%)

71/73, 97.3%

21/73, 28.8%

None (40/45, 88.9%);

Disease exacerbation (2/45, 4.4%);

Herpes zoster (1/45, 2.2%);

Ocular hypertension (1/45, 2.2%);

Dry eyes, weight loss, fatigue, joint pain (1/45, 2.2%)

Rheumatoid arthritis (RA)

15 (12.4%)

Mean: 53.3 ± 12.2

Median: 55.0

Range: 27.0–74.0

M:F

1:0.83

Anterior scleritis (8/15, 53.3%);

Unspecified scleritis (6/15, 40.0%);

Anterior and posterior scleritis (1/15, 6.7%)

NR

Rheumatologic (10/11, 90.9%);

Foster (1/11, 9.1%)

11/11, 100%

2/10, 20.0%

None (8/11, 72.7%);

Infusion hypotension (1/11, 9.1%);

Acute retinal necrosis (1/11, 9.1%);

Itching with infusion (1/11, 9.1%)

GPA and RA

3 (2.5%)

NR

M:F

0.5:1

Anterior scleritis (2/3, 66.7%)

Anterior and posterior scleritis (1/3, 33.3%)

Mean: 9

Median: 8

Range: 5–14

Rheumatologic (2/3, 66.7%);

Oncologic (1/3, 33.3%)

3/3, 100%

2/3, 66.7%

None (2/3, 66.7%);

Bronchitis (1/3, 33.3%);

Bacterial pneumonia (1/3, 33.3%);

Leukopenia (1/3, 33.3%);

Anemia (1/3, 33.3%)

ANCA-associated vasculitis,

not otherwise specified

5 (4.1%)

Mean: 59.6

Median: 59.0

Range: 41.0–78.0

M:F0.67:1

Episcleritis (5/5, 100%)

NR

Rheumatologic (5/5, 100%)

5/5, 100%

NR

None (4/4, 100%)

Other^a

8 (6.7%)

Mean: 52.0 ± 23.7

Median: 53.0 Range: 17.0–81.0

M:F

0.4:1

Anterior scleritis (4/8, 50.0%);

Unspecified scleritis (3/8, 37.5%);

Posterior scleritis (1/8, 12.5%)

NR

Rheumatologic (3/7, 42.9%);

Foster: (2/7, 28.6%);

Other: (2/7, 28.6%)

6/7, 85.7%

0/6, 0%

None (3/4, 75.0%);

Pneumonia and septic shock (1/4, 25.0%)

Indeterminate

15 (12.4%)

Mean: 37.4 ± 15.0

Median: 43.0

Range: 16.0–57.0

M:F

0.22:1

Anterior scleritis (9/15, 60.0%);

Posterior scleritis (2/15, 13.3%);

Unspecified scleritis (4/15, 26.7%)

NR

Rheumatologic (3/8, 37.5%);

Oncologic (2/8, 25.0%);

Foster (2/8, 25.0%);

Other (1/8, 12.5%)

7/9, 77.8%

1/7, 14.3%

None (14/15, 93.3%);

Itcing with infusion (1/15, 6.7%)